Reata Pharmaceuticals Plans NDA Submission for Omaveloxolone

Reata Pharmaceuticals Plans NDA Submission for Omaveloxolone in First Quarter of 2022 Following Completion of Pre-NDA Meeting with FDA

Reata Pharmaceuticals Plans NDA Submission for Omaveloxolone in First Quarter of 2022 Following Completion of Pre-NDA Meeting with FDA

apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

California , United States , Texas , Susan Perlman , Andres Lorente , Los Angeles , Manmeet Soni , University Of California , Department Of Neurology , David Geffen School Of Medicine , European Commission , Drug Administration , Nasdaq , Exchange Commission , Reata Pharmaceuticals Inc , Kyowa Kirin Co Ltd , New Drug Application , United States Food , Warren Huff , Chief Executive , David Geffen School , Orphan Drug , Reata Pharmaceuticals , Annual Report , Business Wire ,